Distinguished in Metastatic Brain Tumor

Wolfgang D. Wick

Heidelberg, BW, DE 
Distinguished in Metastatic Brain Tumor
Heidelberg, BW, DE 
OverviewLocationsClinical Research

Overview

Wolfgang Wick practices in Heidelberg, Germany. Mr. Wick is rated as a Distinguished expert by MediFind in the treatment of Metastatic Brain Tumor. His top areas of expertise are Astrocytoma, Glioblastoma, Glioma, Gliomatosis Cerebri, and Thrombectomy.

His clinical research consists of co-authoring 608 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles in the study of Metastatic Brain Tumor.

Gender
Male

Locations

Heidelberg, BW, Germany
Other Locations
Salem, BW, Germany
Germany
Tuebingen, BW, Germany
Munich, BY, Germany
Magdeburg, ST, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma
Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma
Enrollment Status: Completed
Publish Date: March 08, 2024
Intervention Type: Procedure
An Open-label, Phase I/II Multicenter Clinical Trial of VXM01 in Combination With Avelumab in Patients With Progressive Glioblastoma Following Standard Treatment, With or Without Second Surgery
An Open-label, Phase I/II Multicenter Clinical Trial of VXM01 in Combination With Avelumab in Patients With Progressive Glioblastoma Following Standard Treatment, With or Without Second Surgery
Enrollment Status: Unknown
Publish Date: October 20, 2022
Intervention Type: Biological
Study Drugs: VXM01, Avelumab
Study Phase: Phase 1/Phase 2
A Phase I/II, Randomized, Open-label, Multi-centre Study of BIBF1120 + Reirradiation (R-RT) Versus Reirradiation in the Treatment of Patients With First or Second Progression of Glioblastoma
A Phase I/II, Randomized, Open-label, Multi-centre Study of BIBF1120 + Reirradiation (R-RT) Versus Reirradiation in the Treatment of Patients With First or Second Progression of Glioblastoma
Enrollment Status: Terminated
Publish Date: November 01, 2017
Intervention Type: Drug, Radiation
Study Phase: Phase 1/Phase 2
View 2 Less Clinical Trials

608 Total Publications

Reperfusion-dependent treatment effects of thrombectomy in patients with large ischemic infarcts.
Reperfusion-dependent treatment effects of thrombectomy in patients with large ischemic infarcts.
Journal: International journal of stroke : official journal of the International Stroke Society
Published: October 08, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Wick's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 37 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile